Mirtazapine detection at autopsy does not by itself establish that the drug caused death. Anderson, Fritz and Muto described 13 cases in which the drug was measured in blood and other specimens, yet was not implicated in the cause of death in any case. The findings provide historical case context, not a universal threshold separating safe use from fatal poisoning.
Which cases and specimens were studied?
The Los Angeles County coroner laboratory reported 13 cases encountered over three years. Therapeutic-drug screening was not performed in every death investigation. The authors expressly cautioned that the number of detections did not accurately measure prevalence of mirtazapine use across all coroner cases.
Specimens were collected at autopsy, 24–72 hours after notification of death. That interval is not necessarily the exact time since death. Heart blood received sodium fluoride. Peripheral blood, primarily from the femoral vein, was placed in tubes containing sodium fluoride and potassium oxalate. Other specimens were unpreserved, and all biological specimens were refrigerated at 4°C.
The matrix-specific findings had different denominators
Heart blood contained 0.03–0.57 mg/L in 13 cases. Femoral blood contained 0.04–0.24 mg/L in nine cases. Vitreous was available in only three cases, with concentrations of 0.06–0.10 mg/L. Those three vitreous results cannot establish performance in every mirtazapine-positive death.
Liver concentrations ranged from 0.32 to 2.1 mg/kg in 12 cases; bile from 0.40 to 6.6 mg/L in seven; and urine from 0.12 to 2.5 mg/L in 11. Kidney and spleen measurements came from one case each. Gastric findings in nine cases were reported as total amounts, 0.001–2.7 mg, rather than blood-equivalent concentrations.
These units and denominators matter. A bile concentration above the blood concentration does not automatically mean greater circulating exposure, and a tissue concentration in mg/kg cannot simply be substituted for blood in mg/L.
Screening, quantitation and confirmation were distinct steps
Mirtazapine appeared in the laboratory’s therapeutic-drug screen by gas chromatography with nitrogen–phosphorus detection. A basic extraction using 2 mL of specimen or tissue homogenate supported quantitative analysis on two chromatographic columns. GC–MS comparison with a pure analytical standard provided confirmation.
The reported detection and quantification limits were both 0.025 mg/L, with linearity from 0.025 to 3.0 mg/L and a reported correlation coefficient of 0.999. The article does not provide a complete numerical precision, recovery and matrix-specific validation dataset. Confirmation of chemical identity is a different finding from a causal assessment.
What the authors concluded—and what the design cannot prove
The authors considered the observed concentrations consistent with therapeutic use and interpreted the heart–femoral comparisons as suggesting minimal redistribution at those levels. That conclusion was descriptive. There was no controlled dosing, no matched predeath concentration for the series, and no statistical equivalence test proving that the two blood sites were interchangeable.
Other causes and contributing findings varied substantially across cases, including traumatic injuries, cardiovascular disease, combustion exposure and other drugs. The absence of a mirtazapine-attributed death in this small selected series does not prove that the drug can never contribute to death, alone or with other substances.
Applying the evidence to a report
Identify the actual specimen, collection timing, quantitative method and associated pathology before interpreting a detection. A historical upper observed value is not a fatal cutoff or a guarantee of safety. The paper did not measure behavioral impairment or validate reconstruction of dose from an autopsy concentration.
For the broader problem of comparing different analytes in one body, see co-detected drugs with different postmortem distributions.
Primary source
Anderson DT, Fritz KL, Muto JJ. Distribution of Mirtazapine (Remeron) in Thirteen Postmortem Cases. Journal of Analytical Toxicology. 1999;23:544–548. doi:10.1093/jat/23.6.544.
Leave a Reply